Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study
Abstract Background It has been reported that drugs which promote the N-Methyl-D-aspartate-type glutamate receptor function by stimulating the glycine modulatory site in the receptor improve negative symptoms and cognitive dysfunction in schizophrenia patients being treated with antipsychotic drugs....
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-07-01
|
| Series: | BMC Psychiatry |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12888-017-1410-3 |
| _version_ | 1828768151427350528 |
|---|---|
| author | Kazuo Takiguchi Akihito Uezato Michio Itasaka Hidenori Atsuta Kenji Narushima Naoki Yamamoto Akeo Kurumaji Makoto Tomita Kazunari Oshima Kosaku Shoda Mai Tamaru Masahito Nakataki Mitsutoshi Okazaki Sayuri Ishiwata Yasuyoshi Ishiwata Masato Yasuhara Kunimasa Arima Tetsuro Ohmori Toru Nishikawa |
| author_facet | Kazuo Takiguchi Akihito Uezato Michio Itasaka Hidenori Atsuta Kenji Narushima Naoki Yamamoto Akeo Kurumaji Makoto Tomita Kazunari Oshima Kosaku Shoda Mai Tamaru Masahito Nakataki Mitsutoshi Okazaki Sayuri Ishiwata Yasuyoshi Ishiwata Masato Yasuhara Kunimasa Arima Tetsuro Ohmori Toru Nishikawa |
| author_sort | Kazuo Takiguchi |
| collection | DOAJ |
| description | Abstract Background It has been reported that drugs which promote the N-Methyl-D-aspartate-type glutamate receptor function by stimulating the glycine modulatory site in the receptor improve negative symptoms and cognitive dysfunction in schizophrenia patients being treated with antipsychotic drugs. Methods We performed a placebo-controlled double-blind crossover study involving 41 schizophrenia patients in which D-cycloserine 50 mg/day was added-on, and the influence of the onset age and association with white matter integrity on MR diffusion tensor imaging were investigated for the first time. The patients were evaluated using the Positive and Negative Syndrome Scale (PANSS), Scale for the Assessment of Negative Symptoms (SANS), Brief Assessment of Cognition in Schizophrenia (BACS), and other scales. Results D-cycloserine did not improve positive or negative symptoms or cognitive dysfunction in schizophrenia. The investigation in consideration of the onset age suggests that D-cycloserine may aggravate negative symptoms of early-onset schizophrenia. The better treatment effect of D-cycloserine on BACS was observed when the white matter integrity of the sagittal stratum/ cingulum/fornix stria terminalis/genu of corpus callosum/external capsule was higher, and the better treatment effect on PANSS general psychopathology (PANSS-G) was observed when the white matter integrity of the splenium of corpus callosum was higher. In contrast, the better treatment effect of D-cycloserine on PANSS-G and SANS-IV were observed when the white matter integrity of the posterior thalamic radiation (left) was lower. Conclusion It was suggested that response to D-cycloserine is influenced by the onset age and white matter integrity. Trial registration UMIN Clinical Trials Registry (number UMIN000000468 ). Registered 18 August 2006 |
| first_indexed | 2024-12-11T07:41:35Z |
| format | Article |
| id | doaj.art-32230caeb3984ee4825b59502eea803a |
| institution | Directory Open Access Journal |
| issn | 1471-244X |
| language | English |
| last_indexed | 2024-12-11T07:41:35Z |
| publishDate | 2017-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Psychiatry |
| spelling | doaj.art-32230caeb3984ee4825b59502eea803a2022-12-22T01:15:33ZengBMCBMC Psychiatry1471-244X2017-07-0117111510.1186/s12888-017-1410-3Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover studyKazuo Takiguchi0Akihito Uezato1Michio Itasaka2Hidenori Atsuta3Kenji Narushima4Naoki Yamamoto5Akeo Kurumaji6Makoto Tomita7Kazunari Oshima8Kosaku Shoda9Mai Tamaru10Masahito Nakataki11Mitsutoshi Okazaki12Sayuri Ishiwata13Yasuyoshi Ishiwata14Masato Yasuhara15Kunimasa Arima16Tetsuro Ohmori17Toru Nishikawa18Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental UniversityDepartment of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental UniversityDepartment of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental UniversityDepartment of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental UniversityDepartment of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental UniversityDepartment of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental UniversityDepartment of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental UniversityClinical Research Center, Medical Hospital of Tokyo Medical and Dental UniversityDepartment of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental UniversityOhmiya Kousei HospitalDepartment of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate SchoolDepartment of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate SchoolDepartment of Psychiatry, National Center Hospital of Neurology and PsychiatryDepartment of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental UniversityDepartment of Hospital Pharmacy, Tokyo Medical and Dental UniversityDepartment of Hospital Pharmacy, Tokyo Medical and Dental UniversityDepartment of Psychiatry, National Center Hospital of Neurology and PsychiatryDepartment of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate SchoolDepartment of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental UniversityAbstract Background It has been reported that drugs which promote the N-Methyl-D-aspartate-type glutamate receptor function by stimulating the glycine modulatory site in the receptor improve negative symptoms and cognitive dysfunction in schizophrenia patients being treated with antipsychotic drugs. Methods We performed a placebo-controlled double-blind crossover study involving 41 schizophrenia patients in which D-cycloserine 50 mg/day was added-on, and the influence of the onset age and association with white matter integrity on MR diffusion tensor imaging were investigated for the first time. The patients were evaluated using the Positive and Negative Syndrome Scale (PANSS), Scale for the Assessment of Negative Symptoms (SANS), Brief Assessment of Cognition in Schizophrenia (BACS), and other scales. Results D-cycloserine did not improve positive or negative symptoms or cognitive dysfunction in schizophrenia. The investigation in consideration of the onset age suggests that D-cycloserine may aggravate negative symptoms of early-onset schizophrenia. The better treatment effect of D-cycloserine on BACS was observed when the white matter integrity of the sagittal stratum/ cingulum/fornix stria terminalis/genu of corpus callosum/external capsule was higher, and the better treatment effect on PANSS general psychopathology (PANSS-G) was observed when the white matter integrity of the splenium of corpus callosum was higher. In contrast, the better treatment effect of D-cycloserine on PANSS-G and SANS-IV were observed when the white matter integrity of the posterior thalamic radiation (left) was lower. Conclusion It was suggested that response to D-cycloserine is influenced by the onset age and white matter integrity. Trial registration UMIN Clinical Trials Registry (number UMIN000000468 ). Registered 18 August 2006http://link.springer.com/article/10.1186/s12888-017-1410-3SchizophreniaD-cycloserineGlutamateMR diffusion tensor imagingRandomizedPlacebo-controlled |
| spellingShingle | Kazuo Takiguchi Akihito Uezato Michio Itasaka Hidenori Atsuta Kenji Narushima Naoki Yamamoto Akeo Kurumaji Makoto Tomita Kazunari Oshima Kosaku Shoda Mai Tamaru Masahito Nakataki Mitsutoshi Okazaki Sayuri Ishiwata Yasuyoshi Ishiwata Masato Yasuhara Kunimasa Arima Tetsuro Ohmori Toru Nishikawa Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study BMC Psychiatry Schizophrenia D-cycloserine Glutamate MR diffusion tensor imaging Randomized Placebo-controlled |
| title | Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study |
| title_full | Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study |
| title_fullStr | Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study |
| title_full_unstemmed | Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study |
| title_short | Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study |
| title_sort | association of schizophrenia onset age and white matter integrity with treatment effect of d cycloserine a randomized placebo controlled double blind crossover study |
| topic | Schizophrenia D-cycloserine Glutamate MR diffusion tensor imaging Randomized Placebo-controlled |
| url | http://link.springer.com/article/10.1186/s12888-017-1410-3 |
| work_keys_str_mv | AT kazuotakiguchi associationofschizophreniaonsetageandwhitematterintegritywithtreatmenteffectofdcycloserinearandomizedplacebocontrolleddoubleblindcrossoverstudy AT akihitouezato associationofschizophreniaonsetageandwhitematterintegritywithtreatmenteffectofdcycloserinearandomizedplacebocontrolleddoubleblindcrossoverstudy AT michioitasaka associationofschizophreniaonsetageandwhitematterintegritywithtreatmenteffectofdcycloserinearandomizedplacebocontrolleddoubleblindcrossoverstudy AT hidenoriatsuta associationofschizophreniaonsetageandwhitematterintegritywithtreatmenteffectofdcycloserinearandomizedplacebocontrolleddoubleblindcrossoverstudy AT kenjinarushima associationofschizophreniaonsetageandwhitematterintegritywithtreatmenteffectofdcycloserinearandomizedplacebocontrolleddoubleblindcrossoverstudy AT naokiyamamoto associationofschizophreniaonsetageandwhitematterintegritywithtreatmenteffectofdcycloserinearandomizedplacebocontrolleddoubleblindcrossoverstudy AT akeokurumaji associationofschizophreniaonsetageandwhitematterintegritywithtreatmenteffectofdcycloserinearandomizedplacebocontrolleddoubleblindcrossoverstudy AT makototomita associationofschizophreniaonsetageandwhitematterintegritywithtreatmenteffectofdcycloserinearandomizedplacebocontrolleddoubleblindcrossoverstudy AT kazunarioshima associationofschizophreniaonsetageandwhitematterintegritywithtreatmenteffectofdcycloserinearandomizedplacebocontrolleddoubleblindcrossoverstudy AT kosakushoda associationofschizophreniaonsetageandwhitematterintegritywithtreatmenteffectofdcycloserinearandomizedplacebocontrolleddoubleblindcrossoverstudy AT maitamaru associationofschizophreniaonsetageandwhitematterintegritywithtreatmenteffectofdcycloserinearandomizedplacebocontrolleddoubleblindcrossoverstudy AT masahitonakataki associationofschizophreniaonsetageandwhitematterintegritywithtreatmenteffectofdcycloserinearandomizedplacebocontrolleddoubleblindcrossoverstudy AT mitsutoshiokazaki associationofschizophreniaonsetageandwhitematterintegritywithtreatmenteffectofdcycloserinearandomizedplacebocontrolleddoubleblindcrossoverstudy AT sayuriishiwata associationofschizophreniaonsetageandwhitematterintegritywithtreatmenteffectofdcycloserinearandomizedplacebocontrolleddoubleblindcrossoverstudy AT yasuyoshiishiwata associationofschizophreniaonsetageandwhitematterintegritywithtreatmenteffectofdcycloserinearandomizedplacebocontrolleddoubleblindcrossoverstudy AT masatoyasuhara associationofschizophreniaonsetageandwhitematterintegritywithtreatmenteffectofdcycloserinearandomizedplacebocontrolleddoubleblindcrossoverstudy AT kunimasaarima associationofschizophreniaonsetageandwhitematterintegritywithtreatmenteffectofdcycloserinearandomizedplacebocontrolleddoubleblindcrossoverstudy AT tetsuroohmori associationofschizophreniaonsetageandwhitematterintegritywithtreatmenteffectofdcycloserinearandomizedplacebocontrolleddoubleblindcrossoverstudy AT torunishikawa associationofschizophreniaonsetageandwhitematterintegritywithtreatmenteffectofdcycloserinearandomizedplacebocontrolleddoubleblindcrossoverstudy |